Design and evaluation of inhibitors of enkephalin degrading enzymes. 1988

M C Fournie-Zaluski
Département de Chimie Organique, U 266 INSERM, UA 498 CNRS, UER des Sciences Pharmaceutiques et Biologiques, 4 avenue de l'Observatoire, 75006 Paris, France.

The endogenous opioid peptides enkephalins are degraded in vitro by several metallopeptidases (aminopeptidases, enkephalinase, dipeptidylaminopeptidases). Selective and mixed inhibitors of these enzymes were obtained by a rational approach taking into account crystallographic data on Thermolysin, a bacterial enzyme, used as model of metallopeptidase active site. This strategy is supported by recent cloning of enkephalinase. As expected, a physiological analgesia is produced by administration of inhibitors, especially kelatorphan and analogues, demonstrating unambiguously the implication of enkephalinase and aminopeptidase M in enkephalin metabolism. The intensive studies on endogenous opioid system have shown that inhibitors of enkephalin metabolism represent very useful probes and promising new analgesics.

UI MeSH Term Description Entries

Related Publications

M C Fournie-Zaluski
January 1993, Progress in medicinal chemistry,
M C Fournie-Zaluski
August 1983, Life sciences,
M C Fournie-Zaluski
January 2020, International journal of fertility & sterility,
M C Fournie-Zaluski
September 1987, Drug design and delivery,
M C Fournie-Zaluski
January 2004, Journal of andrology,
Copied contents to your clipboard!